The proposed acquisition does not include shares held by Sun Pharma and its affiliates. After the completion of the deal, Sun Pharma will have a 100% holding in the company.
Motilal Oswal initiates coverage on Adani Enterprises with Buy, sees 25% upside. Here’s why
Motilal Oswal has initiated coverage on Adani Enterprises with a Buy rating and a target price of Rs 3,880, implying 25% upside from the prevailing